RADA16-I

01/01/2022 - "SLan groups show similar wound contraction as control groups (Puramatrix, PBS, and K2), however, showing marked improvement in healing in earlier time points, including increased deposition of new mature blood vessels. "
05/01/2009 - "The wounds treated with either RADA16-I or control materials were carefully examined at morphological, histological and cellular levels. "
05/01/2009 - "Immunohistochemical studies showed that both FGF and EGF were obviously expressed in nascent tissue such as epidermis and glands when wounds were treated with the RADA16-I after injury. "
01/01/2022 - "Wounds are treated with either Low (1 w%) SLan, High (4 w%) SLan, phosphate buffered saline (PBS), Puramatrix, or K2 (an unfunctionalized nonbioactive control sequentially similar to SLan), covered with Tegaderm, and monitored on for a month; animals are sacrificed for histomorphic analyses and immunostaining. "
05/01/2009 - "We found that RADA16-I can advance the time of eschar appearance and the time of eschar disappearance both by 3-5 days, and speed up wound contraction by 20-30% compared with contrast groups (chitosan, poly(DL)-lactic acid (PDLA), collagen I and the blank) without obvious edema. "

01/01/2012 - "We review the current evidence on the use of RADA16-I and describe our experience with its use in rodent models of surgical brain injury. "
12/01/2018 - "In the present study, we accessed the effects of human neural stem/progenitor cells (hNS/PCs) derived from epileptic human brain and human adipose-derived stromal/stem cells (hADSCs) seeded in PuraMatrix hydrogel (PM) on brain function after TBI in an animal model of brain injury. "
01/01/2020 - "In light of the complex pathology of brain injury, the present study evaluated the effects of combination therapy using autologous neural stem/progenitor cells (NS/PCs), PuraMatrix (PM) and curcumin in an animal model of brain injury. "
07/01/2016 - "Preparing neural stem/progenitor cells in PuraMatrix hydrogel for transplantation after brain injury in rats: A comparative methodological study."
01/01/2016 - "Self-assembly peptide nanofibrous scaffold (SAPNS), such as RADA16-I, has been shown to reduce acute brain injury and enhance functional recovery in rat intracerebral hemorrhage (ICH) models. "

04/01/2018 - "The chemosensitivity assay of three ovarian cancer cell lines were significantly different in RADA16-I peptide-coated coverslips compared with 2D dish plates. "
12/17/2009 - "Here, we describe in detail the preparation and use of PuraMatrix, a commercially available self assembling peptide gel that is devoid of animal-derived material and pathogens to encapsulate and propagate the ovarian cancer cell line, OVCAR-5. "
01/01/2011 - "In this study, using RADA16-I peptide hydrogel, a three-dimensional (3D) cell culture model was fabricated for in vitro culture of three ovarian cancer cell lines. "
04/01/2018 - "By 3D cell culture of ovarian cancer cell lines in RADA16-I peptide hydrogel In Vitro, the cell culture model systems was fabricated. "
01/01/2011 - "Using phase contrast microscopy, the appearance of the representative ovarian cancer cells encapsulated in RADA16-I peptide hydrogel on days 1, 3, and 7 in 24-well Petri dishes was illustrated. "

12/17/2009 - "The use of PuraMatrix to culture cancer cells should improve our understanding of the disease and allow us to assess treatment response in more clinically predictive model systems."
12/17/2009 - "PuraMatrix encapsulation of cancer cells."
05/14/2009 - "Our data suggested that nanofiber scaffolds formed by RADA16-I could change tumor microenvironments, and inhibit the growth of tumors. "
05/14/2009 - "However, RADA16-I inhibited the growth of K562 tumors in nude mice. "
12/01/2021 - "It was revealed that RADA16-I can be exploited as a promising carrier for hydrophobic anticancer drugs and has the potential to improve the administration of anticancer drugs to treat cancer effectively with enhanced chemotherapy."

05/14/2009 - "In this study, we investigated the effect of RADA16-I on the growth of human leukemia cells in vitro and in nude mice. "
05/14/2009 - "MTT assay displayed that RADA16-I has no cytotoxicity for leukemia cells and human umbilical vein endothelial cells (HUVECs) in vitro. "
05/14/2009 - "The effect of self-assembling peptide RADA16-I on the growth of human leukemia cells in vitro and in nude mice."